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A BS TR AC T
BACKGROUND
Many patients with coronary artery disease who are not candidates for revascular-
ization have refractory angina despite standard medical therapy. The balloon-
expandable, stainless steel, hourglass-shaped, coronary-sinus reducing device creates 
a focal narrowing and increases pressure in the coronary sinus, thus redistributing 
blood into ischemic myocardium.
METHODS
We randomly assigned 104 patients with Canadian Cardiovascular Society (CCS) 
class III or IV angina (on a scale from I to IV, with higher classes indicating greater 
limitations on physical activity owing to angina) and myocardial ischemia, who 
were not candidates for revascularization, to implantation of the device (treatment 
group) or to a sham procedure (control group). The primary end point was the pro-
portion of patients with an improvement of at least two CCS angina classes at 
6 months.
RESULTS
A total of 35% of the patients in the treatment group (18 of 52 patients), as com-
pared with 15% of those in the control group (8 of 52), had an improvement of at 
least two CCS angina classes at 6 months (P = 0.02). The device was also associated 
with improvement of at least one CCS angina class in 71% of the patients in the 
treatment group (37 of 52 patients), as compared with 42% of those in the control 
group (22 of 52) (P = 0.003). Quality of life as assessed with the use of the Seattle 
Angina Questionnaire was significantly improved in the treatment group, as com-
pared with the control group (improvement on a 100-point scale, 17.6 vs. 7.6 points; 
P = 0.03). There were no significant between-group differences in improvement in 
exercise time or in the mean change in the wall-motion index as assessed by means 
of dobutamine echocardiography. At 6 months, 1 patient in the treatment group 
had had a myocardial infarction; in the control group, 1 patient had died and 3 had 
had a myocardial infarction.
CONCLUSIONS
In this small clinical trial, implantation of the coronary-sinus reducing device was 
associated with significant improvement in symptoms and quality of life in patients 
with refractory angina who were not candidates for revascularization. (Funded by 
Neovasc; COSIRA ClinicalTrials.gov number, NCT01205893.)
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A growing number of patients with severe and diffuse obstructive coronary artery disease who are not candidates for 
revascularization have debilitating angina de-
spite medical therapy.1-3 The worldwide preva-
lence of refractory angina is increasing, and new 
therapeutic options are needed.4
An endoluminal, balloon-expandable, stain-
less steel, hourglass-shaped device designed for 
percutaneous implantation in the coronary sinus 
(Reducer, Neovasc) creates a focal narrowing 
that leads to increased pressure in the coronary 
sinus, which may relieve angina (Fig. 1). A non-
randomized first-in-human study involving 15 
patients with refractory angina who were treated 
with the device showed significant improvement 
with respect to angina class.5 This clinical ben-
efit was maintained at 3 years of follow-up, with 
patency of all the devices documented by means 
of computed tomographic (CT) angiography and 
with no evidence of device migration.6 Recently, 
the outcomes in 21 patients who received the 
device were reported, showing improvement in 
anginal symptoms and in objective measure-
ments of ischemia.7
The development of new therapies for pa-
tients with refractory angina should focus not 
only on reducing the risks of death and myocar-
dial infarction but also on relieving angina and 
improving quality of life.8 The Coronary Sinus 
Reducer for Treatment of Refractory Angina 
(COSIRA) trial examined whether the implanta-
tion of the coronary-sinus reducing device could 
effectively improve angina symptoms in patients 
with obstructive coronary artery disease who 
had concomitant evidence of reversible myocar-
dial ischemia and who were not considered to be 
candidates for revascularization.
ME THODS
STUDY DESIGN AND OVERSIGHT
We conducted this phase 2, multicenter, random-
ized, double-blind, sham-controlled clinical trial 
to test the safety and efficacy of the coronary-
sinus reducing device. The trial was conducted 
at 11 clinical centers and was sponsored by Neo-
vasc. The trial protocol, which is available with 
the full text of this article at NEJM.org, was de-
signed by the academic authors with input from 
the sponsor. The data were collected, managed, 
and analyzed by a contract research organization 
paid by the sponsor. The academic authors had 
full access to the data and take full responsibility 
for the accuracy and completeness of the data 
and the analyses reported, as well as for the fi-
delity of this report to the trial protocol. Six of 
the academic authors wrote the first draft of the 
manuscript and made the decision to submit the 
manuscript for publication.
The trial was overseen by an independent co-
ordinating center, steering committee, clinical-
events committee, and data and safety monitor-
ing board (see the Supplementary Appendix, 
available at NEJM.org). The study protocol and 
amendments, as well as the informed-consent 
form, were reviewed and approved by the relevant 
national authority in each country and by the 
independent ethics committee at each participat-
ing center. The study was conducted in compli-
ance with the provisions of the Declaration of 
Helsinki. All the patients provided written in-
formed consent before enrollment.
STUDY PATIENTS
The inclusion and exclusion criteria for the 
 COSIRA trial have been reported in detail previ-
ously9 and are listed in the Supplementary Ap-
pendix. Patients were considered for participation 
in the trial if they were older than 18 years of age 
and had Canadian Cardiovascular Society (CCS) 
class III or IV angina (on a scale from I to IV, 
with higher classes indicating greater limita-
tions on physical activity owing to angina), de-
spite efforts to control symptoms with medical 
therapy for at least 30 days before screening. 
Medical therapy included beta-blockers, calcium-
channel blockers, nicorandil, ivabradine, and 
short-acting and long-acting nitrates used at 
maximum tolerated doses.10 All the participants 
were required to have evidence of reversible 
myocardial ischemia and a left ventricular ejec-
tion fraction of more than 25%.
Only patients who were not considered to be 
candidates for coronary revascularization were 
eligible to participate in the study, as decided by 
the heart team at each institution on reviewing 
the recent coronary angiographic videos, as de-
tailed previously.11 Patients were excluded if 
they had undergone a recent revascularization 
procedure (≤6 months earlier), had had a recent 
acute coronary syndrome (≤3 months earlier), or 
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had undergone placement of permanent pace-
maker or defibrillator leads in the right heart.
RANDOMIZATION AND INTERVENTION
Candidates meeting the inclusion criteria under-
went right heart catheterization with angiography 
of the coronary sinus before the planned inter-
vention. Only patients with coronary-sinus anat-
omy that was suitable for implantation of the 
device were eligible to undergo randomization 
(for a list of anatomical features that were criteria 
for exclusion, see the Supplementary Appendix).
Participants were randomly assigned in a 
1:1 ratio, with the use of a computer-generated 
random allocation sequence, to undergo either 
implantation of the device (treatment group) or 
the sham procedure (control group). Study as-
signments were concealed in opaque numbered, 
sealed envelopes. The allocation sequence re-
mained concealed until the study groups were 
assigned.9
All the participants were unaware of the study 
assignment throughout the 6-month study period. 
Although the physicians performing the implan-
tation were aware of the study assignments, the 
investigators responsible for assessing the an-
gina class at follow-up, all core laboratory staff, 
the biostatisticians performing the analysis, and 
the members of the clinical-events committee 
were not.
DEVICE DESIGN AND IMPLANTATION
The coronary-sinus reducing device that we eval-
uated is made of stainless steel and is available in 
a single model designed to fit a range of anato-
mies. Its diameter expands with the inflation 
pressure of the semicompliant balloon, which 
has an hourglass shape, and the device conforms 
to the tapering anatomy of the coronary sinus 
(Fig. 1).
Dual antiplatelet therapy was given for at least 
1 week before the procedure and for 6 months 
after the procedure in the two study groups. Pa-
tients randomly assigned to the treatment group 
were treated with intravenous heparin at the time 
of implantation. Participants were offered either 
headsets playing music or conscious sedation to 
mask the conversation in the room regarding the 
Coronary 
sinus
Coronary 
sinus
Catheter
Coronary-sinus 
reducing device
Heart 
(posterior view)
Heart 
Figure 1. Coronary Sinus Reducer System.
The complete system for the coronary-sinus reducing device we evaluated comprises a metal mesh device that is premounted on a balloon 
catheter and is shaped like an hourglass when expanded. After the device is implanted in the coronary sinus, local flow disruption and 
vascular reaction lead to a hyperplastic response in the vessel wall, with occlusion of the fenestrations in the metal mesh. The central orifice 
of the device remains patent and becomes the sole path for blood flow through the coronary sinus, leading to the development of an up-
stream pressure gradient that results in the redistribution of blood from the less ischemic epicardium to the ischemic endocardium.
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randomization and the procedure. The physi-
cians performing the implantation were instruct-
ed to behave similarly during device implantation 
and the sham procedure, including spending a 
similar amount of procedure time per patient, 
regardless of the patient’s study assignment.
A 6-French diagnostic catheter was introduced 
into the right atrium. Right atrial pressure was 
measured and recorded. The catheter was then 
introduced into the coronary sinus, and an angio-
gram was obtained with 30-degree left anterior 
oblique angulation. The implantation site was 
determined according to the vessel diameter; 
side-branch bifurcation was avoided.
In participants assigned to the control group, 
no additional invasive manipulation was per-
formed. In participants assigned to the treat-
ment group, a preshaped 9-French guiding cath-
eter was introduced into the coronary sinus, and 
the device was implanted at the chosen site with 
the use of a 1.1:1.0 ratio of the expanded device 
diameter to the coronary-sinus diameter. Postim-
plantation angiography was performed to ensure 
appropriate implantation.
STUDY END POINTS
The prespecified primary end point was the pro-
portion of patients with an improvement of two 
or more CCS angina classes from baseline to 
6 months after the procedure. Secondary end 
points included the proportion of patients with 
an improvement of one or more CCS classes from 
baseline to 6 months and exercise tolerance as 
assessed with the use of a symptom-limited 
stress test.12,13
Cardiac regional wall motion during stress 
and at rest was assessed by means of dobutamine 
echocardiography at baseline and at 6 months. 
The motion of each of 16 wall segments at rest 
and during peak dobutamine infusion was quanti-
fied (with a score of 1 indicating normal, 2 hypo-
kinetic, 3 akinetic, 4 dyskinetic, and 5 aneurys-
mal),14 and the sum of the wall-motion scores 
for the myocardial segments was divided by the 
number of segments to provide a wall-motion 
index. A modified wall-motion index for the left 
coronary artery was also calculated, with the use 
of 11 segments attributed to the left-coronary-
artery territory.
Angina-related quality of life was assessed 
with the use of the Seattle Angina Question-
naire, which is a 19-item questionnaire that 
measures five domains of health status related 
to coronary artery disease: angina stability, an-
gina frequency, physical limitation, treatment 
satisfaction, and quality of life. Scores range 
from 0 to 100, with higher scores indicating 
fewer symptoms and better health status.15
Technical and procedural success was evalu-
ated, and periprocedural and nonprocedural 
adverse events were recorded. Details of the end-
point assessments are provided in the Supple-
mentary Appendix.
STATISTICAL ANALYSIS
An independent data and safety monitoring board 
was chartered to monitor and evaluate patient 
safety in order to identify any clinically relevant 
trends and advise the steering committee accord-
ingly. Interim analyses, provided to the data and 
safety monitoring board by the contract research 
organization, took place after 30 patients had 
completed 30 days of follow-up and after 50% 
of the originally planned cohort had completed 
6 months of follow-up.
The study was designed to have 80% power to 
test the two-sided hypothesis, at a type I error 
level of 0.05, that 40% of the participants as-
signed to the treatment group would have an 
improvement of two or more CCS angina class-
es, as compared with 15% of the participants 
assigned to the control group. A 10% rate of 
study withdrawal or loss to follow-up was as-
sumed because of uncertainties about deliver-
ability of the device. On the basis of these as-
sumptions, we calculated that we would need to 
enroll 124 participants in the study. Owing to the 
longer-than-expected time to complete enroll-
ment and the lower-than-expected rate of with-
drawal or loss to follow-up, the sponsor elected 
to stop enrollment after 104 patients had under-
gone randomization. The sponsor had no knowl-
edge of the unblinded end-point data when the 
decision to stop enrollment was made; the ran-
domization code was held by the contract re-
search organization.
Continuous variables are described as means 
and standard deviations or as medians and inter-
quartile ranges, as appropriate. Between-group 
differences in means were compared with the 
use of paired Student’s t-tests. Categorical vari-
ables are expressed as proportions and were 
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compared with the use of Pearson’s chi-square 
test or Fisher’s exact test, as appropriate. For con-
tinuous variables in the secondary end points, 
analysis of covariance was used to compare the 
variation in the change from baseline to 6 months 
between the patients in the treatment group and 
those in the control group, after adjustment for 
baseline differences. All the efficacy analyses 
were performed according to the intention-to-
treat principle. The safety analysis, which in-
cluded all the patients who underwent random-
ization, was performed according to the actual 
treatment received. P values of less than 0.05 
were considered to indicate statistical signifi-
cance. No type I error adjustment for multiple 
comparisons was planned. All the analyses were 
performed with the use of SPSS software, ver-
sion 21 (IBM).
R ESULT S
CHARACTERISTICS AT BASELINE
From April 2010 through April 2013, a total of 
104 patients were enrolled in the trial; 52 pa-
tients were assigned to the treatment group and 
52 to the control group. The mean (±SD) age of 
the patients was 67.8±9.4 years (range, 35 to 87), 
and 81% of the patients were men. The study 
population was characterized by high rates of 
risk factors and coexisting conditions (Table 1).
The device was successfully implanted in 50 of 
the 52 patients (96%) randomly assigned to the 
treatment group. In 2 patients, the implantation 
failed owing to a venous valve in the coronary 
sinus that could not be crossed with the device.
EFFICACY END POINTS
Baseline and follow-up information regarding 
CCS angina class was available for all 104 pa-
tients. A total of 18 of 52 patients in the treat-
ment group and 8 of 52 in the control group had 
an improvement of at least two CCS classes (35% 
vs. 15%, P = 0.02) (Fig. 2A). The mean CCS class 
was reduced from 3.2±0.4 at baseline to 2.1±1.0 
at 6 months of follow-up in the treatment group, 
as compared with a reduction from 3.1±0.3 to 
2.6±0.9 in the control group (P = 0.001) (Fig. 2B). 
In the treatment group, 71% of the patients (37 of 
52 patients) had an improvement of at least one 
CCS class, as compared with 42% (22 of 52) in 
the control group (P = 0.003) (Fig. 2A and 3).
Quality of life as measured by the score on 
the Seattle Angina Questionnaire improved by 
17.6 points in the treatment group, as compared 
with 7.6 points in the control group (P = 0.048). 
There were no significant differences between 
the two groups with respect to improvement in 
angina stability (18.1 vs. 8.3 points, P = 0.16) or 
angina frequency (15.3 vs. 11.0 points, P = 0.44) 
(Table S1 in the Supplementary Appendix).
Table 1. Characteristics of the Patients.*
Characteristic
Control  
Group
(N = 52)
Treatment 
Group
(N = 52)
Age — yr 66.0±9.8 69.6±8.7
Male sex — no. (%) 40 (77) 44 (85)
Previous myocardial infarction — no. (%) 30 (58) 27 (52)
Previous CABG — no. (%) 38 (73) 42 (81)
Previous PCI — no. (%) 40 (77) 36 (69)
Hypercholesterolemia — no. (%) 46 (88) 50 (96)
Diabetes mellitus — no. (%) 25 (48) 21 (40)
Hypertension — no. (%) 41 (79) 42 (81)
Current or previous smoking — no. (%) 31 (60) 27 (52)
CCS angina class — no. (%)†
I 0 0
II 0 0
III 45 (87) 42 (81)
IV  7 (13) 10 (19)
Left ventricular ejection fraction 54.8±11.9 53.5±10.2
Antianginal medication — no. (%)
Beta-blocker 40 (77) 40 (77)
Calcium-channel blocker 26 (50) 29 (56)
Nitrates 32 (62) 29 (56)
Nicorandil  6 (12)  7 (13)
Ivabradine  5 (10) 4 (8)
No. of antianginal medications — no. (%)
0 4 (8) 3 (6)
1 10 (19) 10 (19)
2 18 (35) 23 (44)
3 18 (35) 12 (23)
>3 2 (4) 4 (8)
* Plus–minus values are means ±SD. There were no significant differences be-
tween the study groups at baseline. CABG denotes coronary-artery bypass 
grafting, and PCI percutaneous coronary intervention.
† Canadian Cardiovascular Society (CCS) angina classes range from I to IV, with 
higher classes indicating greater limitations on physical activity owing to angina.
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At baseline, the mean total exercise duration 
was 441±191 seconds in the treatment group 
and 464±257 seconds in the control group. At 
6 months of follow-up, the mean exercise dura-
tion had improved by 59 seconds (13%) in the 
treatment group and by 4 seconds (1%) in the 
control group (P = 0.07). The mean time to ST-
segment depression of 1 mm was prolonged by 
49 seconds (13%) in the treatment group and 
by 18 seconds (4%) in the control group (P = 0.41) 
(Table S2 in the Supplementary Appendix).
The change from baseline to 6 months in the 
wall-motion index as assessed by means of do-
butamine stress echocardiography and in the 
modified stress wall-motion index of the left 
coronary artery did not differ significantly be-
tween the two groups. The wall-motion index 
improved by 14% in the treatment group and by 
8% in the control group (P = 0.20). The modified 
stress wall-motion index of the left coronary 
artery improved by 13% in the treatment group 
and by 3% in the control group (P = 0.06) (Table 
S3 in the Supplementary Appendix).
SAFETY END POINTS
A periprocedural myocardial infarction occurred 
in one patient in the treatment group. Other peri-
procedural serious adverse events included un-
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Figure 2. Change in Canadian Cardiovascular Society 
(CCS) Angina Class, According to Study Group.
The proportion of patients with improvement of at least 
two CCS angina classes (primary end point) and the 
proportion with improvement of at least one CCS class 
were significantly higher in the group that received the 
active treatment than in the group that underwent the 
sham procedure (at least two CCS classes, P = 0.02; at 
least one CCS class, P = 0.003) (Panel A). CCS classes 
range from I to IV, with higher classes indicating greater 
limitations on physical activity owing to angina. The 
mean (±SD) CCS class was reduced from 3.2±0.4 at 
baseline to 2.1±1.0 at 6 months of follow-up in the treat-
ment group, as compared with a reduction from 3.1±0.3 
to 2.6±0.9 in the control group (P = 0.001) (Panel B).
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At baseline, no patient in either study group had a CCS angina class of I or II, according to the inclusion criteria for 
the trial.
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stable angina and Crohn’s disease flare (in one 
patient each) in the treatment group and unsta-
ble angina and epigastric pain (in one patient 
each) in the control group.
At least one adverse event was reported in 32 
of 50 patients (64%) who received the device and 
in 37 of 54 patients (69%) who did not receive 
the device (P = 0.68). Overall, 76 adverse events 
were reported in the treatment group, and 93 in 
the control group.
There were three myocardial infarctions and 
one death (due to multiorgan failure at day 118) 
in the control group, and there was one peripro-
cedural myocardial infarction and no deaths in 
the treatment group. There were 34 serious ad-
verse events in the trial (10 events in the treat-
ment group and 24 in the control group). The 
full lists of periprocedural serious adverse events 
and of other serious adverse events are shown in 
Tables S4 and S5, respectively, in the Supplemen-
tary Appendix.
CT angiography was performed in 36 of 50 
patients who received the implant, with no evi-
dence of device migration or occlusion in any of 
the patients. Figure 4 shows a longitudinal view 
and a series of cross-sectional views from a rep-
resentative CT angiographic study performed 
6 months after implantation of the device.
DISCUSSION
We evaluated a coronary-sinus reducing device as 
a new therapy for patients with refractory angina. 
Implantation of the device was significantly 
better than a sham intervention in improving an-
gina symptoms in patients with advanced coro-
nary artery disease who were not candidates for 
revascularization and whose disease was refrac-
tory to standard medical therapy. A reduction of 
at least two CCS angina classes at 6 months (the 
primary end point) occurred 2.4 times as fre-
quently in the treatment group as in the control 
group. Although underpowered for the prespeci-
fied secondary end points, the trial nonetheless 
showed a greater proportion of patients with im-
provement of at least one CCS class and greater 
improvement in quality of life in the treatment 
group than in the control group. Significant dif-
ferences were not seen between the two groups 
with respect to changes in the other secondary 
end points, such as exercise duration, the change 
in the time to ST-segment depression of 1 mm, 
or the change in the wall-motion index.
The prevalence of refractory angina continues to 
increase, owing to its association with aging of the 
population in Western industrialized countries and 
to the increase in the life expectancy of patients 
with ischemic heart disease. Therapeutic options 
that focus on angina relief and improved quality 
of life are needed for this group of patients.4,8,11,16
Figure 4. Representative CT Angiogram of the Device in the Coronary Sinus 
at 6 Months.
Cross-sectional and longitudinal CT angiographic views of the device in the 
coronary sinus show the flow of contrast material, indicating continued pa-
tency 6 months after implantation. The green and red bars in the longitudi-
nal image, on the right, mark the positions of the cross-sectional images 
shown on the left. The red bars that appear in the third cross-sectional im-
age and in the longitudinal image are in the same relative position in the 
two images and mark the positions of the opposing walls of the implant.
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The physiological rationale for a beneficial 
effect of increased coronary sinus pressure in 
angina pectoris remains unclear. In 1954, Beck 
and Leighninger described a surgical procedure 
for partial occlusion of the coronary sinus, 
which was associated with relief of angina, an 
improvement in functional class, and a reduc-
tion in mortality.17-21 The most commonly pro-
posed mechanism of benefit is recruitment of 
coronary collateral flow, with redistribution 
from the less-ischemic epicardium to the isch-
emic endocardium.22-26
Our sham-controlled clinical trial was de-
signed to control for both patient and investiga-
tor biases in the interpretation of the end points. 
A placebo intervention alone can lead to a sub-
stantial improvement in angina symptoms and 
exercise duration.27-32 In a study of transmyocar-
dial laser revascularization for the treatment of 
angina, a pronounced placebo effect was noted, 
with a 30% improvement in exercise duration 
and angina symptoms in the control group of 
patients.33 Consequently, in our trial, extensive 
precautions were taken so that the patients and 
the investigators performing the follow-up would 
be unaware of the study assignments.
Our study was not statistically powered to 
detect an improvement in ischemia by means of 
objective measures such as stress testing or 
wall-motion index. A larger trial would be nec-
essary to show such a benefit. Since the plan-
ning of this study, tools with better fidelity to 
detect improvement in myocardial ischemia, 
such as magnetic resonance imaging and posi-
tron-emission tomography, have become more 
commonplace and would be attractive methods 
to use in phase 3 studies of the coronary-sinus 
reducing device.
In conclusion, this small, double-blind, ran-
domized, sham-controlled trial showed that the 
coronary-sinus reducing device led to a reduc-
tion in symptoms and improved quality of life 
in patients with disabling angina pectoris.
Supported by Neovasc.
Disclosure forms provided by the authors are available with 
the full text of the article at NEJM.org.
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